Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status approved; investigational
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 0480-3610; 60862-005; 69766-030; 76072-1006; 42385-924; 69539-120; 42385-923; 42385-925; 42571-336; 69097-940; 72205-182; 0781-8085; 0480-3611; 65372-1197; 82920-705; 16729-468; 46708-479; 69238-1640; 62332-480; 0781-2158; 62207-004; 31722-872; 50228-442; 69539-119; 57297-140; 73309-052; 46708-480; 69097-988; 69238-1641; 42571-329; 46016-5312; 31722-873; 72205-181; 76282-716; 0781-8086; 53104-7712; 69037-0013; 60219-1640; 60219-1641; 47621-311; 59285-013; 59651-199; 50228-443; 50242-121; 60219-1642; 62332-479; 46016-5310; 16729-467; 42385-926; 42571-335; 50228-441; 50242-122; 69097-987; 76282-715; 76282-717; 11014-0214; 46438-0648; 62512-0070; 50242-123
UNII D7NLD2JX7U
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary arterial hypertension24.08.03.003; 22.06.01.0020.001206%Not Available
Orthostatic hypertension24.08.02.010; 17.05.01.0180.000241%Not Available
Aortic arteriosclerosis24.04.01.004--Not Available
Liver injury12.01.17.012; 09.01.07.0220.000723%Not Available
Regurgitation07.01.07.0040.000530%Not Available
Oropharyngeal pain07.05.05.004; 22.12.03.0160.004774%
Upper-airway cough syndrome22.12.03.0360.000844%
Faeces soft07.01.03.0080.000530%Not Available
Irregular breathing22.02.01.0260.000844%Not Available
Anal incontinence17.05.01.021; 07.01.06.0290.000362%
Abnormal loss of weight14.03.02.0190.000651%Not Available
Chronic respiratory failure22.02.06.005; 14.01.04.0050.001085%Not Available
Dermatitis exfoliative generalised23.03.07.002; 10.01.01.0290.000723%Not Available
Hemiplegic migraine24.03.05.012; 17.14.02.0040.000241%Not Available
Jaw cyst16.11.03.002; 15.02.04.0350.000362%Not Available
Lung adenocarcinoma16.19.01.002; 22.08.01.0070.000482%Not Available
Lung carcinoma cell type unspecified stage IV22.08.01.019; 16.19.02.0060.000362%Not Available
Lymphadenopathy mediastinal22.09.03.006; 01.09.01.0250.000241%Not Available
Throat cancer22.08.02.008; 16.19.02.0070.000241%Not Available
Restrictive pulmonary disease22.01.02.0250.000844%Not Available
Terminal state08.01.03.0790.000362%Not Available
Pulmonary artery dilatation22.06.03.0050.000723%Not Available
Sarcopenia15.05.06.0040.000241%Not Available
Pulmonary pain22.12.01.0100.000362%Not Available
End stage renal disease20.01.03.0190.000241%Not Available
Disease complication08.01.03.0870.000603%Not Available
Hepatic cytolysis09.01.07.0360.000241%Not Available
Illness08.01.03.0910.003448%Not Available
Lung diffusion disorder22.02.07.0220.000482%Not Available
Lung opacity22.12.01.0060.000362%Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages